Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease

British Journal of Ophthalmology

Volumn 93, Issue 11, 2009, Pages 1553-1554

  Niccoli, L ^a   Nannini, C ^a   Cassara E ^a   Gini, G ^b   Lenzetti, I ^b   Cantini, F ^a  

^a MISERICORDIA E DOLCE HOSPITAL   (Italy)

^b HOSPITAL OF PRATO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PREDNISONE;

ABSENCE OF SIDE EFFECTS; ADULT; ALOPECIA; CASE REPORT; CHOROIDITIS; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; LETTER; LUMBAR PUNCTURE; MENINGITIS; OPHTHALMOLOGY; PHYSICAL EXAMINATION; PLEOCYTOSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RETINA DETACHMENT; VISUAL ACUITY; VITILIGO; VOGT KOYANAGI SYNDROME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; TREATMENT OUTCOME; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 70350449424     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.153981     Document Type: Letter

References (6)

1. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease. Semin Ophthalmol 2005;20:183-190
2. Read RW, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2001;131:599-606. (Pubitemid 32422116)
3. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2008;16:167-171
4. Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res 2008;33:517-523
5. Liu L, Yang P, He H, et al. Leptin increases in Vogt-Koyanagi-Harada (VKH) disease and promotes cell proliferation and inflammatory cytokine secretion. Br J Ophthalmol 2008;92:557-561
6. Popa C, Netea MG, van Riel PLCM, et al. The role of TNF-α in chornic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-762 (Pubitemid 46557880)